编者按：当地时间4月29日，ASCO官网公布了今年5月29~31日将以线上会议形式举行的2020 ASCO年会的日程及摘要题目。本文介绍两个肺癌口头报告专场的重要研究。
肺癌-非小细胞局部/小细胞/其他胸部肿瘤口头报告专场
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
顺铂/卡铂和依托泊苷单用或联合纳武利尤单抗一线治疗进展期小细胞肺癌的随机II期临床试验:ECOG-ACRIN EA5161（摘要号9000）
作者: Ticiana Leal， et al.
KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
KEYNOTE-604研究：帕博利珠单抗或安慰剂+依托泊苷和铂类作为广泛期小细胞肺癌患者的一线治疗（摘要号9001）
作者: Charles M. Rudin， et al.
Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study.
德瓦鲁单抗和替西木单抗+铂-依托泊苷化疗在广泛期小细胞肺癌一线治疗的应用: CASPIAN III期研究的最新结果（摘要号9002）
作者:Luis G. Paz-Ares， et al.
PrE0505: Phase II multicenter study of anti-PD-L1， durvalumab， in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.
PrE0505:抗PD-L1抑制剂德瓦鲁单抗联合顺铂和培美曲塞一线治疗不可切除的恶性胸膜间皮瘤的II期多中心研究（摘要号9003）
作者: Patrick M. Forde， et al.
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.
吉西他滨+/-雷莫芦单抗二线治疗晚期恶性胸膜间皮瘤的随机II期研究:意大利Rames研究结果（摘要号9004）
作者: Maria Pagano， et al.
肺癌-转移性非小细胞肺癌口头报告专场
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
纳武利尤单抗+伊匹木单抗 vs.含铂双药化疗作为晚期非小细胞肺癌的一线治疗:CheckMate 227第1部分3年数据更新（摘要号9500）
作者: Suresh S. Ramalingam， et al.
Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
纳武利尤单抗+ 伊匹木单抗+ 2周期含铂双药化疗vs. 4周期化疗作为IV期/复发性非小细胞肺癌的一线治疗: CheckMate 9LA研究（摘要9501）
作者: Martin Reck et al.
CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
CCTG BR.34: 德瓦鲁单抗和替西木单抗+/-铂类为基础的化疗治疗转移性(IV期)鳞状或非鳞状非小细胞肺癌患者的随机试验（摘要号9502）
作者: Natasha B. Leighl， et al.
Primary analysis of a randomized， double-blind， phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
抗TIGIT抗体tiragolumab+阿特珠单抗 vs. 安慰剂+阿特珠单抗一线治疗经PD-L1选择的非小细胞肺癌患者的随机、双盲、II期研究(CITYSCAPE)的初步分析（摘要号9503）
作者: Delvys Rodriguez-Abreu， et al.
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
曲妥珠单抗deruxtecan(T-DXd，前身是DS-8201a)治疗HER2突变转移性非小细胞肺癌患者：DESTINY-Lung01研究中期结果（摘要号 9504）
作者: Egbert F. Smit，et al.
京公网安备 11010502033352号